A recent #CuresNow collaboration between Quest Diagnostics, IBM Watson and Sloan Kettering Cancer Center could help make precise medicine decisions related to best treatments for cancer patients.
This new partnership, named Watson Genomics, could make the supercomputer "Watson" largely accessible to patients and physicians throughout the U.S. for the first time in history. As a result, oncologists could make precise treatment and medicine decisions about certain cancers and clinical trials.
“Under the new service, doctors would send Quest a patient’s tissue sample so that it can be genetically sequenced,” according to a #CuresNow campaign representative. “This genomic information would then be fed to Watson, using its supercomputing powers and Sloan Kettering’s oncology precision medicine database to sift through the latest cancer research and drug trials. The hope is that the process will help doctors more quickly identify the exact treatments that can best serve their patients, since cancer research is an ever-shifting field.”
The goal of the program is to use 21st-century technology to develop and distribute safer, faster cures for diseases. The #CuresNow movement supports this partnership that unites breakthrough discoveries, scientific research and innovation.
Joining these fields could encourage creativity for more technologies like Watson to help with medical dilemmas.
